Jade Biosciences (JBIO) Net Cash Flow (2020 - 2026)
Jade Biosciences' (JBIO) quarterly Net Cash Flow came in at -$33.4 million in Q1 2026, down 404.99% YoY from $10.9 million in Q1 2025, and down 187.03% on a QoQ basis from $38.3 million in Q4 2025.
Jade Biosciences (JBIO) Net Cash Flow (2020 - 2026) Analysis & Trends
Jade Biosciences (JBIO) has 7 years of Net Cash Flow data on file, last reported at -$33.4 million in Q1 2026.
- Quarterly Net Cash Flow fell 404.99% year-over-year to -$33.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.7 million (down 104.7% YoY) and the FY2025 annual result came in at $19.1 million, up 85.79% from the prior year.
- Net Cash Flow declined to -$33.4 million in Q1 2026, from $38.3 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $158.2 million in Q2 2025 to a low of -$170.8 million in Q3 2025.
- A 5-year average of $6.9 million and a median of -$2.9 million in 2022 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 5133.72% in 2023, down 39395.45% in 2023.
- Tracing JBIO's Net Cash Flow over 5 years: stood at -$22000.0 in 2022, then plunged by 39395.45% to -$8.7 million in 2023, then jumped by 1049.65% to $82.5 million in 2024, then tumbled by 53.54% to $38.3 million in 2025, then tumbled by 187.03% to -$33.4 million in 2026.
- The last three Net Cash Flow figures came in at -$33.4 million (Q1 2026), $38.3 million (Q4 2025), and -$170.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Jade Biosciences | 1.57 Bn | 1.11 Bn | - | 52.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 52.25 Mn |
| Jun 30, 2026 | 52.25 Mn |
| Mar 31, 2026 | -33.37 Mn |
| Mar 31, 2026 | -33.37 Mn |
| Dec 31, 2025 | 38.34 Mn |
| Dec 31, 2025 | 38.34 Mn |
| Sep 30, 2025 | -170.83 Mn |
| Sep 30, 2025 | -170.83 Mn |
| Jun 30, 2025 | 158.16 Mn |
| Jun 30, 2025 | 158.16 Mn |
| Mar 31, 2025 | -6.61 Mn |
| Mar 31, 2025 | -6.61 Mn |
| Dec 31, 2024 | 82.52 Mn |
| Dec 31, 2024 | 82.52 Mn |
| Sep 30, 2024 | 87.97 Mn |
| Sep 30, 2024 | 87.97 Mn |
| Mar 31, 2024 | -14.37 Mn |
| Mar 31, 2024 | -14.37 Mn |
| Dec 31, 2023 | -8.69 Mn |
| Dec 31, 2023 | -8.69 Mn |